PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma

Yong Jae Shin, Jason K. Sa, Yeri Lee, Donggeon Kim, Nakho Chang, Hee Jin Cho, Miseol Son, Michael Y.T. Oh, Kayoung Shin, Jin Ku Lee, Jiwon Park, Yoon Kyung Jo, Misuk Kim, Patrick J. Paddison, Vinay Tergaonkar, Jeongwu Lee, Do Hyun Nam

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Glioblastoma (GBM) is the most malignant brain tumor with profound genomic alterations. Tumor suppressor genes regulate multiple signaling networks that restrict cellular proliferation and present barriers to malignant transformation. While bona fide tumor suppressors such as PTEN and TP53 often undergo inactivation due to mutations, there are several genes for which genomic deletion is the primary route for tumor progression. To functionally identify putative tumor suppressors in GBM, we employed in vivo RNAi screening using patient-derived xenograft models. Here, we identified PIP4K2A, whose functional role and clinical relevance remain unexplored in GBM. We discovered that PIP4K2A negatively regulates phosphoinositide 3-kinase (PI3K) signaling via p85/p110 component degradation in PTEN-deficient GBMs and specifically targets p85 for proteasome-mediated degradation. Overexpression of PIP4K2A suppressed cellular and clonogenic growth in vitro and impeded tumor growth in vivo. Our results unravel a novel tumor-suppressive role of PIP4K2A for the first time and support the feasibility of combining oncogenomics with in vivo RNAi screen.

Original languageEnglish
Pages (from-to)1120-1134
Number of pages15
JournalJournal of Experimental Medicine
Issue number5
Publication statusPublished - 2019 May 1
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019 Shin et al.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma'. Together they form a unique fingerprint.

Cite this